Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70317 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Rohini Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. Hauptthemen laut MEDLINE: Drug Approval, Neoplasms, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
This descriptive analysis evaluates design strategies, regulatory outcomes, and temporal trends in oncology accelerated approvals (AAs) over three decades, comparing solid tumors with hematologic malignancies. We retrospectively reviewed publicly available U.S. Food and Drug Administration (FDA) data on oncology drugs granted AA between December 1992 and January 2025, focusing on those with completed post‐approval assessments. Key measures included trial design, endpoints, conversion and withdrawal rates, and time to regulatory resolution. Of 204 AAs representing 204 drug–indication pairs (across 133 drugs), 138 had completed post‐approval assessments; 77.5% converted to regular approval, 22.5% were withdrawn. Solid tumors accounted for 63% (87/138) of AAs, and had higher conversion rates to regular approvals compared to hematologic malignancies (82% vs. 71%, respectively). Withdrawals were more frequent in hematologic malignancies compared to solid tumors (29% vs. 18%, respectively). Orphan drug designation and post‐approval label modifications were more common in hematologic malignancies than solid tumors (76% vs. 45%, and 18% vs. 11%, respectively). Randomized controlled trials (RCTs) drove most successful conversions (63%). Among 105 AA trials for solid tumors, overall response rate (ORR) was the primary endpoint in 74%, with progression‐free survival (PFS) and overall survival (OS) in 13% and 9% AAs, respectively. Hematologic trials favored ORR (33%) and disease‐specific endpoints. The most common AA → confirmatory pathway was ORR → PFS (46%). OS as a confirmatory endpoint after surrogate‐based AA was linked to higher withdrawal rates, whereas consistent endpoints (e.g., OS → OS) had none. RCTs and aligned endpoints drive successful oncology AA conversions, while surrogate‐confirmed OS often precedes withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
- Centre for Studies in Science Policy, School of Social Sciences, Jawaharlal Nehru University, New Delhi, India.
ORCID-Profile: Rohini Sharma
Zitieren
APA
Sharma, R., Gulati, A., & Chopra, K. (2026). Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. International Journal of Cancer. https://doi.org/10.1002/ijc.70317
Vancouver
Sharma R, Gulati A, Chopra K. Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. International Journal of Cancer. 2026. doi:10.1002/ijc.70317
BibTeX
@article{Sharma2026,
author = {Sharma, Rohini and Gulati, Anamika and Chopra, Kanwaljit},
title = {Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70317}
}
EUVIMED